Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)
Xencor (XNCR) shares rose after settling a royalty dispute with Alexion Pharma, a subsidiary of AstraZeneca (AZN). The dispute was related to Ultomiris, a rare disease therapy. Xencor had previously lowered its operating outlook in March due to this issue.
Why it matters
Attributed market update with source link for portfolio context.